These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

71 related items for PubMed ID: 16895939

  • 1. Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand.
    Nuesch R, Srasuebkul P, Ananworanich J, Ruxrungtham K, Phanuphak P, Duncombe C, HIV-NAT Study Team.
    J Antimicrob Chemother; 2006 Sep; 58(3):637-44. PubMed ID: 16895939
    [Abstract] [Full Text] [Related]

  • 2. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.
    Antivir Ther; 2009 Sep; 14(3):339-47. PubMed ID: 19474468
    [Abstract] [Full Text] [Related]

  • 3. Prior antiretroviral therapy experience protects against zidovudine-related anaemia.
    Huffam SE, Srasuebkul P, Zhou J, Calmy A, Saphonn V, Kaldor JM, Ditangco R, TREAT Asia HIV Observational Database (TAHOD).
    HIV Med; 2007 Oct; 8(7):465-71. PubMed ID: 17760739
    [Abstract] [Full Text] [Related]

  • 4. Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384.
    Dubé MP, Parker RA, Mulligan K, Tebas P, Robbins GK, Roubenoff R, Grinspoon SK.
    Clin Infect Dis; 2007 Jul 01; 45(1):120-6. PubMed ID: 17554712
    [Abstract] [Full Text] [Related]

  • 5. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida.
    Enferm Infecc Microbiol Clin; 2009 Apr 01; 27(4):222-35. PubMed ID: 19246124
    [Abstract] [Full Text] [Related]

  • 6. Adverse drug reactions associated with antiretroviral treatment among adult Ethiopian patients in a tertiary hospital.
    Abdissa SG, Fekade D, Feleke Y, Seboxa T, Diro E.
    Ethiop Med J; 2012 Apr 01; 50(2):107-13. PubMed ID: 22924279
    [Abstract] [Full Text] [Related]

  • 7. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
    Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, LeBraz M, Jupimai T, Ubolyam S, Schutz M, Hirschel B, Staccato Thailand Study Group.
    Antivir Ther; 2008 Apr 01; 13(3):375-80. PubMed ID: 18572750
    [Abstract] [Full Text] [Related]

  • 8. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
    Kitkungvan D, Apisarnthanarak A, Laowansiri P, Mundy LM.
    HIV Med; 2008 Oct 01; 9(8):636-41. PubMed ID: 18643857
    [Abstract] [Full Text] [Related]

  • 9. Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.
    Kline MW, Rugina S, Ilie M, Matusa RF, Schweitzer AM, Calles NR, Schwarzwald HL.
    Pediatrics; 2007 May 01; 119(5):e1116-20. PubMed ID: 17420261
    [Abstract] [Full Text] [Related]

  • 10. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008.
    Sungkanuparph S, Anekthananon T, Hiransuthikul N, Bowonwatanuwong C, Supparatpinyo K, Mootsikapun P, Chetchotisakd P, Kiertiburanakul S, Tansuphaswadikul S, Buppanharun W, Manosuthi W, Techasathit W, Ratanasuwan W, Tantisiriwat W, Suwanagool S, Leechawengwongs M, Ruxrungtham K, Thai AIDS Society.
    J Med Assoc Thai; 2008 Dec 01; 91(12):1925-35. PubMed ID: 19133532
    [Abstract] [Full Text] [Related]

  • 11. Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy.
    Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V.
    HIV Med; 2008 May 01; 9(5):317-21. PubMed ID: 18331562
    [Abstract] [Full Text] [Related]

  • 12. Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.
    Llibre JM, Domingo P, del Pozo MA, Miralles C, Galindo MJ, Viciana I, Moreno S, Schapiro JM, Clotet B.
    J Antimicrob Chemother; 2008 Jan 01; 61(1):206-9. PubMed ID: 17999972
    [Abstract] [Full Text] [Related]

  • 13. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P, Ungsedhapand C, Ruxrungtham K, Boyd MA, Phanuphak P, Cooper DA, Law MG.
    HIV Med; 2007 Jan 01; 8(1):46-54. PubMed ID: 17305932
    [Abstract] [Full Text] [Related]

  • 14. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ, Su Z, Havlir DV, Robertson KR, Coombs RW, Cain P, Peterson T, Krambrink A, Jahed N, McMahon D, Margolis DM, AIDS Clinical Trials Group 5170 Study Team.
    J Infect Dis; 2007 May 15; 195(10):1426-36. PubMed ID: 17436222
    [Abstract] [Full Text] [Related]

  • 15. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
    Huttner AC, Kaufmann GR, Battegay M, Weber R, Opravil M.
    AIDS; 2007 May 11; 21(8):939-46. PubMed ID: 17457087
    [Abstract] [Full Text] [Related]

  • 16. Characteristics of HIV-infected tuberculosis patients in Thailand.
    Mankatittham W, Likanonsakul S, Thawornwan U, Kongsanan P, Kittikraisak W, Burapat C, Akksilp S, Sattayawuthipong W, Srinak C, Nateniyom S, Tasaneeyapan T, Varma JK.
    Southeast Asian J Trop Med Public Health; 2009 Jan 11; 40(1):93-103. PubMed ID: 19323040
    [Abstract] [Full Text] [Related]

  • 17. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
    Launay O, Duval X, Dalban C, Descamps D, Peytavin G, Certain A, Mouajjah S, Ralaimazava P, Verdon R, Costagliola D, Clavel F, ANRS 109 VISTA Study Group.
    Antivir Ther; 2006 Jan 11; 11(7):889-99. PubMed ID: 17302251
    [Abstract] [Full Text] [Related]

  • 18. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
    Blümer RM, van Vonderen MG, Sutinen J, Hassink E, Ackermans M, van Agtmael MA, Yki-Jarvinen H, Danner SA, Reiss P, Sauerwein HP.
    AIDS; 2008 Jan 11; 22(2):227-36. PubMed ID: 18097225
    [Abstract] [Full Text] [Related]

  • 19. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
    Bergroth T, Ekici H, Gisslén M, Loes SK, Goh LE, Freedman A, Lampe F, Johnson MA, Sönnerborg A.
    J Med Virol; 2009 Jan 11; 81(1):1-8. PubMed ID: 19031460
    [Abstract] [Full Text] [Related]

  • 20. Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
    Spire B, Marcellin F, Cohen-Codar I, Flandre P, Boue F, Dellamonica P, Raffi F, Norton M, Van Philippe N, Delfraissy JF.
    Antivir Ther; 2008 Jan 11; 13(4):591-9. PubMed ID: 18672538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.